Pancreatic Cancer - Pipeline Review, H1 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Pancreatic Cancer - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Pancreatic Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 146, 138, 2, 11, 289, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 11, 2, 1, 48 and 7 molecules, respectively.
Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:Introduction Pancreatic Cancer - Overview Pancreatic Cancer - Therapeutics Development Pancreatic Cancer - Therapeutics Assessment Pancreatic Cancer - Companies Involved in Therapeutics Development Pancreatic Cancer - Drug Profiles Pancreatic Cancer - Dormant Projects Pancreatic Cancer - Discontinued Products Pancreatic Cancer - Product Development Milestones Appendix For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vwzhv5/pancreatic_cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006063/en/
Laura Wood, Senior Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Pancreatic Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/25/2018 02:33 PM/DISC: 09/25/2018 02:33 PM